UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/542,983	07/21/2005	Horst G. Zerbe	AML/13131.19	7824	
61114 BCF LLP				EXAMINER	
1100 RENE'-LE'VESQUE BLVD. WEST			AHMED, HASAN SYED		
	25TH FLOOR MONTREAL, QC H3B-5C9 CANADA		ART UNIT	PAPER NUMBER	
CANADA			1618		
			MAIL DATE	DELIVERY MODE	
			06/27/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/542,983	ZERBE ET AL.		
Office Action Summary	Examiner	Art Unit		
	HASAN S. AHMED	1618		
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING Description of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin 1 will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed on <u>27 M</u> This action is FINAL . 2b) ☑ This action is application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro			
Disposition of Claims				
4) Claim(s) 1-15,17-19,28 and 30 is/are pending 4a) Of the above claim(s) 2-15,17-19,28 and 3 5) Claim(s) is/are allowed. 6) Claim(s) 1 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	30 is/are withdrawn from considera	ation.		
Application Papers				
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examin	cepted or b) objected to by the lead of a drawing(s) be held in abeyance. Section is required if the drawing(s) is objection	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate		

DETAILED ACTION

Receipt is acknowledged of applicants' response to the restriction requirement (filed on 27 May 2008).

* * * * *

Election/Restrictions

Applicants' election with traverse of Group I in the reply filed on 27 May 2008 is acknowledged. The traversal is on the ground that the layers of Plachetka are expanding circles around a core while the instant application discloses layers disposed in a linear fashion. This is not found persuasive because applicants have not claimed layers disposed in a linear fashion. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

It should be noted that claims 28 and 30 recite process claims, which is a different statutory class of invention from Group I. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to

Application/Control Number: 10/542,983 Page 3

Art Unit: 1618

be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

The requirement is still deemed proper and is therefore made FINAL.

Claims 2-15, 17-19, 28, and 30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 27 May 2008.

* * * * *

Information Disclosure Statement

The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a

Application/Control Number: 10/542,983 Page 4

Art Unit: 1618

separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

* * * * *

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 4,946,685 ("Edgren").

Edgren discloses a multilayer oral dosage form comprising:

- the matrix core comprising a therapeutically effective amount of a first drug wherein the matrix core allows sustained release of the first drug of instant claim 1(a) (see col. 6, line 55 col. 7, line 54; figure 3, 13 and 14);
- the first layer in contact with the core comprising a therapeutically effective amount of a second drug wherein the first layer allows sustained release of the first drug of instant claim 1(b) (see col. 6, line 55 col. 7, line 54; figure 3, 12 and 14); and
- the second layer in contact with the core comprising a therapeutically effective amount of a second drug wherein the second layer allows immediate release of the second drug of instant claim 1(c) (see col. 6, line 55 col. 7, line 54; figure 3, 15 and 16).

Application/Control Number: 10/542,983 Page 5

Art Unit: 1618

水

Correspondence

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to HASAN S. AHMED whose telephone number is

(571)272-4792. The examiner can normally be reached on 9am - 5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Michael G. Hartley can be reached on (571)272-0616. The fax phone

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/H. S. A./

Examiner, Art Unit 1618

/Humera N. Sheikh/ Primary Examiner, Art Unit 1618 Application/Control Number: 10/542,983

Page 6

Art Unit: 1618